In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 51 to 100 of 412

TitleTypeExpected publication date
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462Technology appraisal guidanceTBC
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]Technology appraisal guidance
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]Technology appraisal guidanceTBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]Technology appraisal guidanceTBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Technology appraisal guidanceTBC
Bipolar disorder: assessment and management (extraordinary review)NICE guidelineTBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]Technology appraisal guidance
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]Technology appraisal guidanceTBC
Breast cancer guidelinesNICE guidelineTBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Technology appraisal guidance
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325](review of TA677)Technology appraisal guidance
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]Technology appraisal guidanceTBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]Technology appraisal guidanceTBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]Technology appraisal guidance
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]Technology appraisal guidanceTBC
Cardiometabolic disease prevention and treatment guidelinesNICE guidelineTBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Technology appraisal guidance
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Highly specialised technologyTBC
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failureNICE guidelineTBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Technology appraisal guidanceTBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]Technology appraisal guidanceTBC
Cladribine for treating relapsing multiple sclerosis [ID6263]Technology appraisal guidance
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Technology appraisal guidanceTBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessmentHealth technology evaluationTBC
Colon cancer (adjuvant) - irinotecan [ID379]Technology appraisal guidanceTBC
Compression products for treating venous leg ulcers: late stage assessmentHealth technology evaluation
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitisInterventional procedures guidance
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]Technology appraisal guidanceTBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]Technology appraisal guidance
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over [ID6140]Technology appraisal guidanceTBC
Dapagliflozin for treating chronic kidney disease [ID6411]Technology appraisal guidance
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Technology appraisal guidanceTBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidance
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Technology appraisal guidanceTBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]Technology appraisal guidance
DCVax-L for treating glioblastoma [ID836]Technology appraisal guidanceTBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]Technology appraisal guidanceTBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897Technology appraisal guidanceTBC
Delgocitinib for treating moderate to severe chronic hand eczema ID6408Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]Technology appraisal guidanceTBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726Technology appraisal guidanceTBC
Diabetic retinopathy - ruboxistaurin [ID382]Technology appraisal guidanceTBC
Digital front door for people accessing NHS Talking TherapiesHealth technology evaluation

Results per page

  1. 10
  2. 25
  3. 50
  4. All